CT-2A Syngeneic Model Overview
The CT-2A syngeneic model is a murine glioblastoma multiforme (GBM) system derived from C57BL/6 mice. It was developed by inducing astrocytoma formation through chemical mutagenesis, resulting in a high-grade glioma that closely mirrors the histological and biological complexity of human glioblastoma. CT-2A tumors are highly aggressive, exhibit poor immunogenicity, and are characterized by rapid growth, extensive vascularization, and an immunosuppressive tumor microenvironment.
This model is particularly valuable for studying immune checkpoint resistance, tumor-associated macrophage function, and mechanisms of immune exclusion within the central nervous system. When implanted intracranially, CT-2A cells form invasive tumors that replicate the diffuse infiltration, necrosis, and vascular proliferation typical of human GBM. The model’s immune-competent C57BL/6 background makes it highly suitable for testing immunotherapies, oncolytic viruses, radiation, and drug delivery systems targeting brain tumors.
Request a Custom Quote for CT2A Syngeneic ModelBiological and Molecular Characteristics
The CT-2A cell line was established from a chemically induced astrocytoma in C57BL/6 mice. It is composed of heterogeneous glial cells with high proliferative and invasive capacity. CT-2A tumors are molecularly defined by activation of MAPK and PI3K signaling pathways, overexpression of vascular endothelial growth factor (VEGF), and upregulation of immunosuppressive cytokines such as TGF-beta and IL-10. The result is a rapidly growing glioma with a dense stromal matrix and strong immune evasion capacity.
Compared with the GL261 model, CT-2A exhibits lower baseline immunogenicity and reduced responsiveness to checkpoint inhibition, making it an excellent system for evaluating strategies that reprogram the tumor microenvironment toward immune activation. The microenvironment contains abundant tumor-associated macrophages, microglia, and myeloid-derived suppressor cells, with limited T-cell infiltration. This immune profile closely parallels human glioblastoma, supporting translational immunotherapy studies.
| Parameter | Description |
|---|---|
| Host strain | C57BL/6 (female, 6–8 weeks) |
| Tumor origin | Chemically induced astrocytoma (mouse) |
| Histological type | High-grade glioma / glioblastoma multiforme |
| Inoculation route | Intracranial or subcutaneous |
| Tumor take rate | >90% |
| Doubling time | Approximately 3–4 days in vivo |
| Metastatic potential | Local brain invasion; no systemic spread |
| Immunophenotype | Immune-cold; macrophage and microglia dominated |
| Common applications | Immunotherapy resistance, radiation therapy, oncolytic virus testing, CNS drug delivery |
In Vivo Model Development and Tumorigenicity
The CT-2A model is most commonly established by intracranial implantation of tumor cells into C57BL/6 mice using stereotactic guidance. Tumors develop within 7–10 days, showing rapid expansion and infiltration into adjacent brain tissue. The intracranial model is ideal for replicating glioblastoma’s local invasiveness, hypoxia, and immune suppression. Alternatively, subcutaneous implantation can be used for convenient monitoring of tumor growth and drug response, though it lacks the CNS-specific immune context.
CT-2A tumors are aggressive and exhibit limited response to single-agent checkpoint inhibitors, reflecting the immune-excluded phenotype of human glioblastoma. Because of this resistance, CT-2A is often used to test combination strategies that integrate radiotherapy, cytokine delivery, or immune modulators. The model’s reproducibility, low immunogenicity, and invasive behavior make it particularly well suited for evaluating next-generation therapies that aim to overcome immunotherapy resistance in the brain.
Request a Custom Quote for CT2A Syngeneic ModelHistopathology and Immunohistochemical Profile
Histological examination of CT-2A tumors reveals pleomorphic glial cells with hyperchromatic nuclei, prominent nucleoli, and a diffuse infiltrative growth pattern. Tumors display regions of pseudopalisading necrosis, microvascular proliferation, and perivascular cuffing of immune cells—hallmarks of human glioblastoma. The tumor–brain interface shows reactive gliosis and neuronal displacement, reflecting invasive CNS pathology.
Immunohistochemical staining demonstrates strong expression of glial fibrillary acidic protein (GFAP), confirming astrocytic origin, and high Ki-67 labeling, consistent with rapid proliferation. CD31 staining highlights a dense vascular network, while F4/80 and Iba1 staining indicate prominent macrophage and microglial infiltration. T-cell infiltration is sparse, with scattered CD3-positive lymphocytes primarily at the tumor margins. PD-L1 expression is high and inducible, reinforcing the model’s utility for studying checkpoint inhibitor resistance. The CT-2A tumor’s invasive and immunosuppressive phenotype closely parallels that of human GBM, supporting its use in translational neuro-oncology research.
Preclinical Applications and Drug Response
The CT-2A syngeneic model is widely employed in glioblastoma research to study tumor immunology, immune evasion, and therapeutic resistance. It has been used to evaluate radiation therapy, immune checkpoint inhibitors, and oncolytic viral vectors. Due to its poor responsiveness to single-agent immunotherapy, CT-2A is an ideal system for assessing combination regimens that integrate checkpoint blockade with radiation, adoptive T-cell therapy, or cytokine-based immune activation.
This model is also used in studies of macrophage and microglia reprogramming, as well as testing nanoparticle and gene delivery systems designed to penetrate the blood–brain barrier. Radiotherapy combined with immunostimulatory agents such as IL-12 or GM-CSF has shown enhanced anti-tumor activity in this model. The CT-2A system remains a cornerstone for developing therapeutic strategies that target both the immunological and stromal barriers of glioblastoma.
Request This Model
To request the CT-2A syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for CT2A Syngeneic Model